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Summary 
T cell costimulation by molecules on the antigen presenting cell (APC) is required for optimal 
T cell proliferation.  The B7 molecule on APC binds the T lymphocyte receptor CD28, triggering 
increased interleukin 2 (IL-2) production and subsequent T cell proliferation. CTLA-4 is a predicted 
T  cell membrane receptor homologous to CD28, which also binds the B7 counter receptor, 
but whose distribution and function are unknown. Here we have developed monodonal antibodies 
(mAbs) specific for CTLA-4 and have investigated these questions, mAbs were produced that 
bound CTLA-4 but not CD28, and that blocked binding of CTLA-4 to B7. CTLA-4 expression 
as measured by these mAbs was virtually undetectable on resting T cells, but was increased several 
hundred-fold during T cell activation. On activated lymphocytes, CTLA-4 was expressed equally 
on CD4 + and CD8 + T cell subsets and was coexpressed with CD25, CD28, and CD45RO. 
CTLA-4 expression was lower than that of CD28, reaching a maximum of "~1/30-50 the level 
of CD28. Despite its lower expression,  CTLA-4 was responsible for much of the B7 binding 
by large activated T cells. Anti-CTLA-4 mAb 11D4 and anti-CD28 mAb 9.3 acted cooperatively 
to inhibit T cell adhesion to B7, and to block T cell proliferation in primary mixed lymphocyte 
culture. When coimmobilized with anti T cell receptor (TCR) mAb, anti-CTLA-4 mAbs were 
less effective than anti-CD28 mAb 9.3 at costimulating proliferation of resting or activated T 
cells. However, coimmobilized combinations of anti-CD28 and anti-CTLA-4 were synergistic 
in their ability to augment anti-TCR-induced proliferation of preactivated CD4 + T cells. These 
results indicate that CTLA-4 is coexpressed  with CD28 on activated T lymphocytes and cooperatively 
regulates T  cell adhesion and activation by B7. 
T  lymphocyte activation requires occupancy of the TCR 
by antigenic peptides in the context of MHC molecules 
on the APC. Other T  cell surface molecules interact with 
specific counter receptors on the APC to receive costimula- 
tory signals that regulate the outcome of TCR occupancy 
(1, 2). T cell activation in vitro in the absence of costimula- 
tion results in development of antigen-specific unresponsive- 
ness by clonal anergy (2, 3), or activation-induced cell death 
(4). The molecular basis for T cell costimulation is not dearly 
understood, but may involve several different T cell surface 
receptors and their counter receptors on the APC (5). 
CD28 is a T cell surface receptor that delivers important 
costimulatory signals.  CD28  mediates a T  cell activation 
pathway that has been extensively studied using mAbs (6). 
These studies have led to the conclusion that CD28 is an 
important regulator of T cell cytokine production by tran- 
scriptional (7, 8) and posttranseriptional (9) mechanisms. More 
recent studies have suggested a role for CD28 in regulation 
of clonal anergy, mAbs to CD28 augmented T cell prolifera- 
tion in the presence of costimulation-deficient  APC (10), and 
reversed development of clonal anergy in T cell clones (11). 
A  counter receptor for CD28 is B7 (12), a molecule first 
identified as a B lymphocyte activation antigen (13). B7 has 
been shown to costimulate proliferation of human (14-17) 
and murine T  cells (18, 19). 
CTLA-4 is a predicted T  cell surface molecule that was 
identified by differential screening of a murine cytolytic-T cell 
cDNA library (20). CTLA-4 transcripts were found in T cell 
populations having cytotoxic activity, leading to the sugges- 
tion that CTLA-4 might function in the cytolytic response 
(20, 21). CTLA-4 bears structural homology to CD28 (22, 
23), and genes for these molecules colocalize to the same chro- 
mosomal regions in human (24) and mouse (23, 25). Like 
CD28,  CTLA-4 also binds the B7 counter receptor (26). 
CTLA4Ig, an immunoglobulin Fc fusion of the extracellular 
domain of CTLA-4, bound B7 with an avidity '~20-fold 
higher than an analogous CD28Ig fusion protein, and blocked 
alloantigen responses in vitro (26). CTLA4Ig administration 
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jection  (28). 
The normal function of CTLA-4 is unknown.  It is un- 
clear why distinct counter receptors for B7 have evolved. Until 
now,  a protein product of the CTLA-4 gene has not been 
identified, and its cellular distribution and role in normal T 
cell immune responses are unknown. To address these prob- 
lems, we have prepared mAbs specific for CTLA-4.  In this 
study, we have used these reagents to address the distribu- 
tion  and function of CTLA-4 during  T  cell activation. 
Materials and Methods 
mAbs.  Murine  mAbs  9.6  (anti-CD2),  G19-4  (anti-CD3), 
G17-2 and 66.1 (anti-CD4), G10.1 (anti-CDS), 9.3 (anti-CD28), 
and rat mAb 187.1 (antimurine Ig r  chain)  have been described 
previously (29-32). mAb 4G7 (anti-CD19) was a gift of E. En- 
gleman (Stanford University, Stanford, CA) and UCHbl  (anti- 
CD45KO) was from P. Beverly (University College, London, UK). 
mAb WT31 (anti-TCK) was purchased from Becton Dickinson 
& Co. (San Jose, CA) and mAb M23 (antibreast tumor mucin) 
was  acquired from Genetic Systems  Corp.  (Seattle,  WA).  mAb 
7G7/B6 (anti-CD25) was obtained from the American Type Cul- 
ture Collection (RockviUe,  MD). 
Cell Culture.  B7 + CHO cells have been previously described 
(14, 26) and were maintained in DMEM supplemented with 10% 
fetal bovine serum (FBS) 1, 0.2 mM proline, and  1 I~M metho- 
trexate. COS cells were maintained in DMEM supplemented with 
10%  FBS. 
T  cells were cultured in lymphocyte culture medium (RPMI 
1640 medium containing 10% FBS, 100 U/ml penicillin,  and 100 
gg/ml streptomycin). PBL were isolated by centrifugation through 
lymphocyte separation medium (LSM;  Organon Teknika Corp., 
Durham, NC). PHA-activated T cells were prepared by culturing 
PBL with 1 #g/ml PHA (Wellcome Diagnostic, Charlotte, NC) 
in lymphocyte culture medium for 6 d, then in lymphocyte culture 
medium lacking PHA for 1 d. Viable cells were collected by sedimen- 
tation through LSM before use. Enriched CD4 + or CD8 + popu- 
lations were isolated by complement-mediated lysis of CD8 + or 
CD4 + T cells (labeled with mAbs G10.1 or 66.1, respectively) be- 
fore PHA  activation.  The resulting CD4 + culture was  "~90% 
CD4 +, 2% CD8+; and the CD8 § culture, "~95% CD8* and 1% 
CD4 +, as judged by flow cytometry. In some experiments, PBL 
were also activated by immobilized anti-CD3 mAb G19-4. Plastic 
wells were coated with a solution of mAb G19-4 at 20 #g/ml in 
PBS for '~2 h at 37~  and washed with PBS before addition of PBL. 
CD4 + T  cells were isolated  from PBL by immunomagnetic 
negative selection (33) and cultured in lymphocyte culture medium. 
The selection procedure routinely yielded preparations of >95% 
CD4 + cells. Alloantigen-primed CD4 § T  cells were generated 
from MI.C ofCD4 + T cells with an irradiated (10,000 rad) EBV- 
transformed lymphoblastoid cell  line  from an  unrelated donor 
(DK2/DR4).  At weekly intervals,  cells were refed with fresh ir- 
radiated lymphoblastoid calls and II.-2 (20 U/ml) as previously de- 
scribed (33). Viable cells were isolated before use by sedimentation 
1 Abbreviations used in this paper: EIA, enzyme immunoassay; FBS, fetal 
bovine serum; HRP, horseradish  peroxidase;  LFE, linear fluorescence  units; 
LSM, lymphocyte  separation  medium; PE-SA, R-phycoerythrin-conjugated 
streptavidin. 
through LSM. In some experiments, viable cells were rested for 
",d6-24 h in lymphocyte culture medium before use. Alloantigen- 
primed cells were cultured for 3-7 wk with weekly restimulation. 
CD4 §  T  cells were also  activated  by coimmobilized anti-TCR 
mAb  WT31  with  intraceUular  adhesion  molecule  1  receptor 
globulin  (ICAM-1  Kg)  fusion  protein  (33).  Round  bottomed 
96-well microtiter plates  were coated with goat anti-mouse and 
anti-human Ig, followed by mAb WT31 and ICAM Rg at 25 ng 
per well (33).  CD4 § T cells were added  (5  x  104 per well) and 
cultured for 3 d at 37~ 
Plasmids and Transfections.  Expression plasmids OMCD28 and 
OMCTLA-4 have been described (26). cDNA inserts from these 
plasmids were subcloned into the lrLN expression vector (provided 
by Dr. A. Aruffo, Bristol-Myers Squibb Pharmaceutical Research 
Institute) and transfected into COS cells (14). Cell surface expres- 
sion was analyzed 48-72 h after transfection. CTLA4 (mur)Ig was 
a genetic fusion identical to CTLA4Ig (26), except that the human 
Ig portion was replaced with the analogous fragment from murine 
Ig C~/2a. Ig fusion proteins were purified from serum-free condi- 
tioned medium of transfected COS cells (14). Transfected COS cells 
were l~SI-surface  labeled using lactoperoxidase,  and H~O~, extracts 
were prepared and subjected to immunoprecipitation analysis as de- 
scribed (14). Cells cotransfected with OMCD28 and OMCTLA-4 
were analyzed by two-color flow cytometry to determine the de- 
gree of coexpression of CD28 and CTLA-4. 34% of cells expressing 
CD28 also expressed CTLA-4, and 72% of cells expressing CTLA-4 
expressed  CD28. 
mAb Production.  BALB/c mice were primed subcutaneously 
with  CTLA-4(mur)Ig  (*50  #g/mouse)  in  Titermax  adjuvant 
(CytRx Corp., Norcross, GA). Secondary and tertiary immuniza- 
tions were given intraperitoneally in PBS. 3 d after the third im- 
munization, the spleen was removed and spleen cells were fused 
(34) with murine myeloma Ag8.653.  Hybrids were screened on 
day 11 by enzyme immunoassays  (EIA) for antibodies that bound 
immobilized CTLA4Ig. EIA reagents were obtained commercially 
(Genetic Systems Corp.). Cells in positive wells were cloned by 
limiting dilution. 
EIA.  For hybridoma screening, microtiter plates (Immulon 2; 
Dynatech Laboratories,  Inc.,  Chantilly,  VA)  were coated with 
1 #g/ml CTLA4Ig for 16.-24 h at 4~  Wells were blocked for 
I h with sample diluent (Genetic Systems Corp.), then washed with 
PBS containing 0.05% Tween 20. Hybridoma supematants were 
added and incubated at 23~  for 1 h. After washing, horseradish 
peroxidase (HKP)-conjugated goat anti-mouse Ig conjugate (Tago 
Inc., Burlingame, CA) was added and plates were again incubated 
for I h at 23~  Finally, plates were washed thoroughly, and 3,Y,5,5' 
tetramethylbenzidine (TMB) substrate (Genetic Systems Corp.) was 
added.  For measurement of CTLA-4 and CD28 levels in cell ex- 
tracts,  microtiter plates were coated with mAb 11D4 or 9.3 at 1 
gg/ml in PBS. Nonionic detergent extracts of cells were prepared 
as for immunoprecipitation studies  (14) and were added to plates 
for 1 h at 23~  Plates were washed, and biotinylated mAb 7F8 
or 9.3 were added for CTLA-4 or CD28 determinations, respec- 
tively. After an additional 1-h incubation, plates were washed again 
before addition of a HRP-streptavidin (SA) conjugate (Jackson Im- 
munoresearch Laboratories,  Inc., West Chester, PA). Plates were 
again incubated for 1 h, then washed extensively,  and finally, de- 
veloped by addition of o-Phenylenediamine (OPD) substrate (Sigma 
Chemical Co., St. Louis, MO). Enzyme reactions proceeded for 
'~30 min, and were stopped by the addition of an equal volume 
of 1 N H2SO4. Absorbance at 450 nm (TMB) or 490 nm (OPD) 
were recorded on a microtiter plate reader (Genetic Systems Corp.). 
The amount of CTLAo4 or CD28 in each sample was determined 
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binant CD28Ig (14) or CTLA4Ig (26) as standards. The linear range 
of the CTLA-4 EIA was ,'o0.2-10 ng/ml CTLA4Ig, and the CD28 
EIA, ~20-1,000  ng/ml CD28Ig.  The CTLA-4 EIA showed no 
detectable crossreactivity  with CD28Ig, and the CD28 EIA showed 
no  detectable crossreactivity for  CTLA-4.  Neither  assay gave 
significant signals with extracts from cells that did not express 
CTLAo4 (by RNA blot analysis)  or CD28 (by cell surface  staining). 
Immunostaining and Flow Cytometry.  Ceils were collected by 
sedimentation and incubated with saturating amounts of mAbs 
in DMEM containing 10% FBS for 1-2 h at 4~  When indirect 
immunofluorescence was measured, binding was detected by addi- 
tion of a FITC goat anti-mouse  Ig reagent (Tago Inc.), or by 
R-PE--conjugated  SA (PE-SA, Molecular  Probes, Inc., Eugene, OR). 
Cells were then analyzed on a flow cytometer (Epics C; Coulter 
Electronics Inc., Hialeah, FL). 
Cell Adhesion Assays.  T cell adhesion to B7 + CHO cells was 
measured  by modification  of a published  procedure (12). Monolayers 
of B7 § CHO cells were fixed in situ with 0.5% paraformaldehyde 
in PBS for 20 min at 23~  Cells were then washed and incubated 
in lymphocyte culture medium for 1 h before addition of T cells. 
AUoactivated CD4 § T cells were SlCrqabeled and preincubated for 
I h at 23~  with or without mAbs in lymphocyte  culture medium. 
Labeled T cells were added to B7 § CHO monolayers, and adhe- 
sion reactions were initiated by brief centrifugation to bring cells 
in contact. Background cation-dependent adhesion  was minimized 
by addition of EDTA (10 mM) to lymphocyte culture medium. 
Adhesion was allowed to proceed for 1-2 h at 37~  Nonadherent 
cells were removed by washing monolayers four times with lym- 
phocyte culture medium. Adhesion was quantified by measuring 
monolayer bound radioactivity in a gamma counter. 
RNA Blot Analysis.  RNA was prepared from stimulated PHA 
blasts (,,ol-3  x  107Aamph) by a rapid isolation procedure (35). 
RNA  (10  #g)  was fractionated on  formaldehyde agarose gels, 
transferred, and crosslinked to zetaprobe (Bio-Rad Laboratories, 
Richmond, CA). Blots were prehybridized and hybridized with 
32p-labeled probes (36). CD28 probes were a 342-bp fragment cor- 
responding to amino acids 4-117 of the predicted mature CD28 
sequence; or full-length CD28 cDNA (37). The CTLA-4 probe 
was a 375-bp fragment corresponding to amino acids 1-125 of the 
predicted CTLA-4 protein sequence (22). The CD8 probe was a 
,~l.3-kb  fragment of a CD8 cDNA clone provided by Dr. Jan 
Chalupny (Bristol-Myers  Squibb Pharmaceutical  Research Institute). 
The GAPDH probe has been previously  described (14). DNA frag- 
ments were gel purified and 32p-labeled using a random priming 
kit (Boehringer Mannheim Corp., Indianapolis, IN). Blots were 
sequentially hybridized with different 32p-labeled probes. Between 
hybridizations, probe was stripped from the blots by boiling in a 
solution of SSC (0.15 M NaC1, 0.015 M sodium citrate) containing 
0.1% SDS. 
M/Z?.  PBL were prepared by density gradient centrifugation 
on Ficoll-Hypaque. The cells were resu.spended in medium con- 
taining RPMI 1640, 25 mM Hepes, 1 U/ml penicillin, 1 #g/ml 
streptomycin, and 15% pooled human serum that had been heat 
inactivated at 56~  for 30 min. Responder and stimulator cells 
were unrelated individuals chosen so that there was at least one 
HLA class I and one HLA-DK antigen mismatched within each 
pair. Equal numbers (5  x  104 per well each) of responder and ir- 
radiated stimulator cells (3,000 tad) were cultured in the presence 
or absence of mAbs in round-bottomed 96-well  plates. These were 
incubated at 37~  in a 5%  CO2 atmosphere. Assays were per- 
formed  in  triplicate.  Cultures  were pulsed with  one  #Ci  of 
[3H]thymidine 18 h before harvesting. 
Results 
Regulation of Transc@ts  for CTLA-4.  We first compared 
the  expression  and  regulation  of CTLA-4  transcripts  in 
CD4 + or CD8 + T  cells. CD4 + and CD8 + enriched lym- 
phocyte populations were obtained by complement-mediated 
lysis  of CD8 +  and  CD4 +  T  cells,  respectively,  and  the 
resulting populations were activated with PHA and rested 
as described in Materials and Methods. Transcripts for CTLA-4 
were detected at similar levels in RNAs from both CD4 + 
and CD8 + subsets.  Low levels of two CTLA-4 transcripts 
of "~1.8 and '~0.6 kb were detected in CD4 + and CD8 + 
enriched ceils (Fig. 1 A). The '~l.8-kb transcript was reduced 
in the resting CD4 + enriched population shown in Fig.  1 
A, but not in another experiment. Both transcripts were in- 
creased in CD4 + and CD8 + enriched populations by stim- 
ulation with crosslinked anti-CD28 mAb and with PMA. 
Crosslinked anti-CD2 mAb was less effective at inducing 
CTLA-4  transcripts.  Levels of  CTLA-4  transcripts  in 
alloantigen-primed CD4 + cells at various times after acti- 
vation were examined in Fig. 1 B. CTLA-4 transcripts were 
absent from rested alloantigen reactive T cells, but accumu- 
lated during activation, reached a peak at •24  h and there- 
after decreased.  Thus, CTLA-4 transcripts are expressed in 
both CD4 + and CD8 + T cells after activation by CD28 en- 
gagement, by PMA, or by alloantigen activation. 
Preparation and Characterization of mAbs for CTLA-4.  To 
aid in studies of the distribution and function of CTLA-4, 
we prepared mAbs specific for this molecule as described in 
Materials and Methods. We selected a panel of 14 anti-CTLA-4 
mAbs, of which three (11D4,  10A8, and 7F8) were selected 
for further study. All three mAbs were of the IgG1 isotype. 
In initial characterization experiments, these three mAbs bound 
strongly to CTLA-4-transfected COS ceils or immobilized 
CTLA4Ig, but not to CD28-transfected COS cells or im- 
mobilized CD28Ig. Studies of mAbs binding to a panel of 
mutant CTLA4Ig proteins indicated that epitopes for these 
mAbs are dependent upon protein conformation rather than 
contiguous amino acid sequence  (data not shown).  These 
mAbs  also  inhibited binding of CTLA4Ig to  B7 + CHO 
cells (Fig. 2 A), with mAb 10A8 requiring lower concentra- 
tions to block equivalently (half-maximal inhibition at *0.03 
#g/m1, as compared with 0.1-0.2/~g/ml for 11D4 and 7F8). 
This suggests that all three mAbs bind to biologically active 
(or "native") CTLA-4 at or near the binding site for B7. In 
other experiments, mAb 10A8 competed for binding ofbio- 
tinylated 11D4 to CTLA-4, but mAb 7F8 did not. This indi- 
cates that mAbs 11D4 and 10A8 bind spatially related epi- 
topes, whereas the epitope for 7F8  was distinct. 
mAb 11D4 was also characterized by immunoprecipitation 
analysis (Fig. 2 B). COS cells were transfected with OMCD28, 
OMCTLA-4, or a mixture of the two plasmids, 12SI-surface 
labeled and subjected to immunoprecipitation analysis with 
different mAbs and Ig fusion proteins. B7Ig and mAb 9.3, 
but  not mAb  11D4,  immunoprecipitated an "~72,000-Mr 
protein (under nonreducing conditions) from CD28-trans- 
fected COS cells. This species is known from other experi- 
ments (14, 37)  to be a disulfide-linked homodimer. Lesser 
1597  Linsley  et al. Figure 1.  Regulation  of  CTLA-4  transcripts  by T cell  activation. (A) Regulation  of CTLA-4  expression  in different  T cell subsets. PBL were  depleted 
of CD8 + or CD4 + T cells and activated  with PHA as described  in Materials and Methods. Calls (2  x  107)  were then stimulated for 4 h at 37~ 
with medium alone; with anti-CD28 mAb 9.3, or anti-CD2 mAb 9.6 at 2 #g/ml for 10 min at 37~  followed  by mAb 187.1 (antimurine  Ig K  chain) 
at 10 #g/m1; or with PMA (10 ng/ml). Cells  were  harvested,  and RNA was extracted  and analyzed  by blot analysis. The blot was sequentially  hybridized 
with 32P-labeled  probes for CTLA-4, CD8, or GAPDH, as described in Materials and Methods. Migration positions are noted of the 28S and 18S 
ribosomal RNA species visualized by ethidium bromide staining. (B) Regulation of CTLA-4 transcripts during alloactivation. Resting alloantigen- 
primed CD4 + T cells (2  x  107) were collected  and restimulated with irradiated lymphoblastoid  ceUs. Cells were harvested at the indicated times, 
and RNA was extracted  and analyzed  by blot analysis as described  in Fig. 1  A. (Bottom) Ribosomal  RNA bands visualized  by ethidium  bromide  staining 
before transfer. 
amounts of the nondisulfide-linked monomer (an ",,37,000 
Mr) were also precipitated with the mAb. The *72,000-Mr 
protein found in the lane precipitated with CD5Ig was due 
to spillover and was not seen in other experiments, mAb 9.3 
was more effective at immunoprecipitation than B7Ig, which 
agrees with the greater affinity of the mAb (14).  B7Ig and 
mAb  11D4  immunoprecipitated primarily an  "~40,O00-Mr 
protein from cells transfected with CTLA-4. In another ex- 
periment, we found proteins immunoprecipitated by B7Ig 
migrated with "o27,000 Mr upon reduction. B7Ig immuno- 
precipitated  "o72,000  and  40,O00-Mr proteins  from  COS 
cells transfected with both CD28 and CTLA-4. The larger 
of these was immunoprecipitated by mAb 9.3, and the smaller 
by mAb 11D4. Thus, mAb 11D4 specifically immunoprecipi- 
tates CTLA-4 from mixtures with CD28. These experiments 
provided no evidence of disulfide-linked complexes between 
CD28  and  CTLA-4. 
Quantitation of CTLA-4 and CD28 Expression during Allo- 
activation.  Initial attempts to use anti-CTLA-4 mAbs to stain 
T  cells from peripheral blood suggested that CTLA-4 was 
expressed at low levels. To monitor CTLA-4 expression, we 
used mAbs to nonoverlapping epitopes on CTLA-4 to de- 
velop  a  sandwich  EIA  for  this  molecule  as  described  in 
Materials and Methods. Biotinylated mAb 7F8 was used to 
detect CTLA-4 that had been immobilized by mAb 11D4. 
This assay could detect concentrations of CTLA4Ig of <0.2 
ng/ml  but  gave  no  detectable signal  at  concentrations of 
CD28Ig of up to 10/zg/ml.  CTLA-4 concentrations were 
then determined in lymphocyte cell extracts by comparison 
with a standard curve constructed with known concentra- 
tions of CTLA4Ig. Extracts of activated lymphocytes that 
gave transcripts for CTLA-4 (PHA-activated T  cell blasts, 
and activated CD4 + cytotoxic T  cell clones) tested positive 
in the CTLA-4 sandwich EIA, but cells that lacked CTLA-4 
transcripts were negative (resting CD4 + T  cell clones,  lym- 
phoblastoid cell lines,  T  cell leukemias Jurkat  and  CEM). 
Expression of CTLA-4 protein during activation of alloanti- 
gen-primed CD4 + cells (Fig. 3) followed the time course of 
transcript expression (Fig.  1 B).  CTLA-4 was undetectable 
in resting cells (< ~0.04 fmoles/106 cells or ~25 molecules/ 
cell) and peak protein levels were measured at 1 d after acti- 
vation  (~10  fmoles/106  cells  or  ~6,000  molecules/cell). 
Thus,  expression of CTLA-4 was  induced ~>250-fold by 
a11oactivation. 
For comparison, CD28 levels in the same  extracts were 
measured using a similar EIA (Fig. 3). In this case, mAb 9.3 
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Ratio of CTLA-4 to CD28 increases during  alloactivation 
of primed CD4 + cells. Resting, viable-primed CD4 + cells were restimu- 
lated with irradiated lymphoblastoid cells. At the indicated times, cells 
were collected, extracted with nonionic detergent (14), and amounts of 
CD28 (I) and CTLA-4 (A) in the extract were measured by sandwich 
EIAs, as described in Materials and Methods. Shown are means and SD 
(Mrs) of measurements made with three serial dilutions that fell within 
the linear region of standard curves for each sample. The value  for CTLA-4 
at day 0 represents a maximal estimate since this measurement was below 
the linear portion  of the standard curve. 
Figure 2.  Characterization of anti-CTLA-4 mAbs. (A) Anti-CTLA-4 
mAbs block binding of CTLA4Ig to B7. Biotinylated-CTLA41g  (10 ng/ml 
final concentration) was incubated for 1 h at 23~  with the indicated con- 
centrations of anti-CTLA-4 mAbs 7F8 (II), 10A8 (Q), or 11D4 (A); or 
with isotype control mAb M23 (O). B7 + CHO cells were removed from 
their culture vessel  by incubation in PBS containing 10 mM EDTA, col- 
lected by centrifugation, incubated with the mAb/biotinyl-CTLA4Ig mix- 
ture for "~1 h at 23~  and washed. Binding of biotinyl-CTLA4Ig was 
then detected with PE-SA, and cells were analyzed by flow cytometry. 
Mean fluorescence  values were recorded and converted to linear fluores- 
cence units (LFU). Background fluorescence ('~2 LFU) was subtracted 
from all values. Values are expressed  as percentage of maximal fluorescence 
in the absence of mAb (',~13 LFU). (B) Immunoprecipitation of CTLA-4 
from transfected COS cells. COS cells (',,106) were transfected with equal 
amounts of expression plasmids OMCD28, OMCTLA-4,  or a mixture 
of these two plasmids. 48 h after transfection, cells were detached from 
their culture dishes with EDTA, and subjected to cell surface iodination 
and immunoprecipitation analysis (14) with the indicated Ig molecules 
at 20/~g/ml.  CD5Ig (human IgG1) and mAb M23 (routine IgG1) were 
used as controls. SDS-PAGE  was performed on a 10-20% acrylamide gel 
run under nonreducing conditions. The migration  of standard proteins 
is indicated. 
was used as both capture and detecting mAb,  and CD28Ig 
was used as standard. The ability ofmAb 9.3 to both capture 
and  detect  CD28  probably  reflects  that  this  molecule  is 
homodimeric.  The CD28 sandwich EIA did not show reac- 
tivity with CTLA-4Ig at concentrations of up to 10/zg/ml, 
nor did it show reactivity with extracts from a lymphoblastoid 
cell line that does not express CD28.  CD28 levels in extracts 
from antigen-primed CD4 + T  cells also increased during ac- 
tivation, but less than those for CTLA-4. The ratio of CTLA-4 
to CD28 therefore increased during alloactivation, reaching 
a  maximum of ,x,1:30 between  1  and  2  d  after  activation. 
Cell  Surface  Expression  of  CTLA-4  on  Activated  T 
Cells.  Having determined  the kinetics of CTLA-4 expres- 
sion, we next investigated its surface expression. Preliminary 
experiments showed that when alloactivated, primed CD4 + 
T  cells were stained with biotinylated  mAb  11D4  and  ana- 
lyzed by flow cytometry, the intensity of staining with mAb 
11D4 varied depending upon light scatter profile of the popu- 
lation  analyzed.  Staining  was brighter  on  a  subpopulation 
of larger activated cells. This staining was specific since unla- 
beled  mAb  11D4  (but  not  an isotype control  mAb)  com- 
peted for staining by biotinylated mAb 11D4. The main popu- 
lation of activated cells and resting cells stained less intensely. 
Thus,  surface expression of CTLA-4 was greater on larger, 
activated cells.  Similar findings  are demonstrated  below  in 
Fig.  5. 
Surface expression of CTLA-4 was also detected  on PBL 
activated with immobilized anti-CD3 mAb, and on purified 
CD4 §  T  cells  activated with  immobilized anti-CD3  mAb 
or with a coimmobilized combination of anti-TCR mAb and 
ICAM-1  Rg  (33).  Surface expression  of CTLA-4  was  not 
detected on resting cells, but became detectable  after 2-4 d 
of activation.  In all cases, staining was brighter on a popula- 
tion of larger, activated cells which comprised 5-20% of the 
total  cell population,  of which  up  to  ~50%  stained  with 
mAb 11D4. When PBLs activated for 3 d with immobilized 
anti-CD3  were pulse labeled with  BrdU  and  stained  with 
FITC-labeled anti-BrdU mAb (38), the larger activated popu- 
lation  had  an '~two-fold higher  percentage of stained  cells 
(in S phase) than for the bulk population.  No difference in 
BrdU  incorporation  was seen in  11D4  positive or negative 
1599  Linsley  et al. cells, indicating that CTLAo4 expression is not restricted to 
cells  in S phase.  The distribution  of CTLA-4 on different 
T cell subsets was examined in the experiment shown in Fig. 
4. Results presented are for the larger activated subpopula- 
tion, although qualitatively similar results were also seen when 
the total population was analyzed.  CTLA-4 surface expression 
was detected on CD4 + and CD8 + cells. CTLA-4 was coex- 
pressed with CD25, CD28, and CD45KO. Thus, CTLA-4 
is expressed on a fraction of the activated CD28 + T cells of 
both  CD4 + and  CD8 + subsets. 
Cooperation of CTLA-4 and CD28 in Mediating Adhesion 
to B7.  Since CTLA-4 and CD28 were coexpressed on T cells, 
it was important  to determine the relative contributions of 
these molecules towards adhesion to B7. In previous studies 
(26), we showed that CTLA4Ig bound B7 with greater avidity 
than did CD28Ig, which suggested that CTLA-4 is a higher 
avidity receptor for B7 than is CD28. Expression of CTLA-4 
on activated T  lymphocytes might  then be expected to in- 
crease their binding to B7. We took two approaches towards 
testing this possibility. In one approach, CD4 + T cells from 
PBL were activated by coimmobilized anti-TCK plus ICAM-1 
R.g and tested for their ability to bind biotinylated B7Ig (Fig. 
5).  Large,  activated cells  expressed more CTLA-4 and also 
expressed approximately twofold more CD28 than the smaller 
cell population. Comparison of mean fluorescence values in- 
dicated that  large,  activated cells expressed "oS0-fold more 
CD28 than CTLA-4, assuming equivalent detection of the 
two mAbs. Large, activated cells also bound more B7Ig (Fig. 
5). Binding of B7Ig to both large and small cell populations 
was stronger when the concentration  of biotinylated B7Ig 
was increased, but for this experiment the concentration of 
B7Ig used was minimized  so as to more easily compete for 
B7Ig binding with mAbs. B7Ig binding was blocked by both 
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Figure 4.  CTLA-4 expression 
by subsets of anti-CD3 activated 
T  lymphocytes.  PBL were  acti- 
vated by incubation with immobi- 
lized anti-CD3 mAb for 2 d at 
37~  Cells  were collected  and 
stained  without  or  with  bi- 
otinylated mAb 11D4. Cells were 
washed and then incubated with 
PE-SA without  or with  FITC- 
conjugated  mAbs  G17.2  (anti- 
CD4), 10.1 (anti-CDS),  7G7/B6 
(anti-CD25), 9.3 (anti-CD28), or 
UCHL-1  (anti-CD45RO). Cells 
were then subjected to two-color 
analysis by flow cytometry. Shown 
are contour plots  obtained  from 
two  independent  experiments. 
Results shown are from larger ac- 
tivated cells, although qualitatively 
similar results were also obtained 
with smaller cells. Staining with 
biotinylated  mAb 11D4 was in- 
hibited by prior incubation of  cells 
with excess  unlabeled mAb 11D4, 
but not with an excess ofisotype- 
matched  control mAb. 
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Figure 5.  B7 binds  better to T lymphocytes  expressing the CTLA-4 
counter receptor. CD4 § T cells were activated by culturing for 3 d with 
coimmobilized anti-TCR mAb WT31 with ICAM-1 Rg fusion protein. 
Cells were collected and stained with medium alone, or with biotinylated 
mAbs 9.3 or 11D4 (middle) or with biotinylated  B71g (bottom), all at 10 
#g/ml. Where indicated,  binding of biotinylated  B7Ig was blocked by 
preincubation  with an excess (100 #g/ml) of unlabeled mAbs 9.3,  11D4, 
or with 9.3 plus 11D4. B7Ig binding was detected by addition  of PE-SA, 
and analyzed by flow cytometry. Control experiments showed that binding 
of biotinylated-B7Ig  was blocked by an excess of unlabeled B7Ig, but not 
by an irrelevant  human  Ig,  or by an irrelevant  murine IgG1 mAb. 
mAbs 11D4 and 9.3, but not by a control mAb of irrelevant 
specificity.  Identical results were obtained when PBL were 
activated with immobilized anti-CD3 mAb before staining. 
These findings indicate that large activated cells bind more 
B7 than smaller cells, and that both CTLA-4 and CD28 con- 
tribute to this increased binding, despite the great difference 
in  abundance  of the two molecules. 
We also examined the relative contributions  of CTLA-4 
and  CD28  on activated T  cells  towards binding  B7 using 
a cellular adhesion assay. In these experiments, antigen-primed 
CD4 + T cells were alloactivated,  SlCr-labeled,  and tested for 
their ability to adhere to B7 + CHO cells in the presence of 
increasing  amounts  of anti-CD28  mAb 9.3 or a combina- 
tion of anti-CD28 mAb 9.3 plus anti-CTLA-4  mAb 11D4 
(Fig.  6). mAb 9.3 inhibited CD4 + T  cell adhesion to B7 + 
CHO cells in a dose-dependent fashion,  mAb  11D4 alone 
at 1 #g/ml did not significantly affect adhesion when com- 
pared with an irrelevant control mAb. The addition of 1/~g/ml 
mAb 11D4 to increasing concentrations of mAb 9.3 resulted 
in a shifting of the dose-response curve approximately five- 
fold to the left. Thus, mAb 11D4 was synergistic with mAb 
9.3 at inhibiting  adhesion of activated T  cells to B7. Iden- 
tical results were obtained in three different experiments.  These 
data indicate that CTLA-4 and CD28 cooperatively mediate 
adhesion  to B7. 
Functional Cooperation between CTLA-4 and CD28 during 
T Cell Activation.  The involvement of CTLA-4 and CD28 
in costimulation during primary MLC was examined (Fig. 
7). Anti-CD28 and anti-CTLA-4 mAbs were used alone and 
in combination to block involvement of these molecules in 
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Figure 6.  Anti-CD28 and anti-CTLA-4 mAbs cooperatively  inhibit adhe- 
sion of activated  CD4 + cells to B7 + CHO cells. Adhesion  of alloacti- 
vated (24 h) slCr-labeled CD4* T cells to fixed monolayers of B7 + CHO 
cells was measured  as described in Materials and Methods.  T cells were 
incubated with 1/~g/ml anti-CTLA-4 mAb 11D4 (O) or isotype control 
mAb M23 ([]); or with the indicated concentrations  of mAb 9.3 mixed 
with 1 #g/ml mAbs 11D4 (e) or M23 (II) before initiation of adhesion. 
Adhesion was allowed to proceed for I h at 37~  and nonadherent  cells 
were removed by washing.  Monolayers were solubilized  by addition  of 
1 N NaOH, and bound radioactivity was measured with a gamma counter. 
Values are expressed as a percentage of adhesion measured in the absence 
of mAb (5,400 cpm, 3,800  cells, or •6%  of input cells). 
proliferation during primary MLC. In these experiments, Fab 
fragments ofmAb 9.3 were used since these are more efficient 
inhibitors of MLC (39).  mAb 11D4 at 5/~g/ml did not in- 
hibit primary MLC, but increased by "~10-fold  the ability 
of various concentrations of Fab fragment of mAb 9.3 to in- 
hibit  MLC.  These data suggest  that  CTLA-4  and CD28 
cooperatively regulate T  cell proliferative responses during 
MLC. 
Experiments were performed to demonstrate effects of anti- 
CTLA-4 mAbs on T  cell proliferation. We observed that, 
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Figure 7.  Anti-CD28 and anti-CTLA-4 mAbs cooperatively inhibit pri- 
mary MI.A2. Primary  MLC with HLA-DR mismatched  responder  and 
stimulator cells was performed in the presence of 5/~g/ml of anti-CTLA-4 
mAb I1D4 alone (A); or with the indicated concentrations  of Fab frag- 
ment ofanti-eD28 mAb 9.3 alone (m) or together with 5 #g/ml ofmAb 
11D4 (e). Means of cpm incorporation  of three replicates were calculated. 
Data for each treatment are represented as a percentage of the peak prolifer- 
ative response in untreated cultures  (30,500  cpm), 
in contrast to anti-CD28 mAb 9.3 (6), mAb I1D4 did not 
significantly augment anti-CD3 or PMA-induced prolifera- 
tion of PBL during 3-d cultures. Since CTLA-4 expression 
is activation dependent, we also tested the ability of mAb 
11D4 to augment proliferation ofT cells that had been preac- 
tivated for 3 d with anti-TCR mAb and ICAM-1 Kg (33). 
Coimmobilization of anti-TCR mAb and anti-CD28 mAb 
9.3 greatly increased proliferation of these cells (Fig. 8). Coim- 
mobilized combinations of anti-TCR mAb and anti-CTLA- 
4 mAb 11D4 increased proliferation slightly. In some experi- 
ments, this combination of mAbs gave greater enhancement 
of proliferation, but always less than the combination of anti- 
TCR mAb plus anti-CD28 mAb. Coimmobilization of anti- 
TCK mAb plus a combination of mAbs 9.3 and 11D4 gave 
synergistic effects on proliferation. When anti-TCR mAb was 
omitted, proliferation was insignificant (data not shown), in- 
dicating that the proliferative effects of mAbs 11D4 and 9.3 
also required TCR activation. Similar results were obtained 
with anti-CTLA-4 mAb 10A8.  Thus, mAbs to CD28 and 
CTLA-4 were synergistic in their ability to costimulate preac- 
tivated CD4 + T  cells. 
Discussion 
CTLA-4 was identified as a transcript encoding a "cyto- 
toxic T lymphocyte-associated" molecule (20). Here we have 
shown that CTLA-4 is expressed at similar levels on both 
CD4 + and CD8 + T  cell subsets,  and is coexpressed with 
the CD25 activation marker. CTLA-4 expression is regulated 
in similar fashion on both CD4 + and CD8 + T cell subsets. 
Expression of CTLA-4 is therefore not restricted to cytotoxic 
T  cellS,  but rather more generally, to activated T  lympho- 
cytes. Our results also show that CTLA-4 and CD28 are not 
generally expressed on reciprocal subsets  of T  cells,  as has 
been speculated (40). Instead, CTLA-4 was coexpressed with 
its homologue CD28 on a subset of activated T  cells. 
Cells that expressed the highest levels of CTLA-4 (detected 
by mAb 11D4) also bound more of the B7Ig fusion protein, 
partly as a result of CTLA-4 expression, since B7Ig binding 
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Figure 8.  Anti-CTLA-4 and anti-CD28 mAbs synergistically costimu- 
late proliferation  of primed CD4 + T  lymphocytes.  CD4 + T cells from 
PBL were activated by culturing for 3 d with coimmobilized anti-TCR 
mAb WT31 with ICAM-1 Rg fusion protein as described in Fig. 5. Cells 
were then collected and cultured with 20 ng/well WT31 (anti-TCR) plus 
40 ng/well negative control mAb 4G7 (anti-CD19);  or 20 rig/well each 
ofmAb 4G7 and mAbs 9.3 (anti-CD28) or 11D4 (anti-CTLA-4);  or with 
20 ng/well each of mAbs 9.3 and 11D4. Proliferation  was measured by 
addition of pH]thymidine (1/zCi/well) during the final 16 h of a 3-d cul- 
ture at 37~  Shown are results from triplicate  cultures  (_+  SD).  Wells 
from which anti-TCR mAb was omitted gave <1,000  cpm. 
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was expressed much less than CD28 on this cell population 
(*50-fold less) it bound a significant fraction of the total 
B7Ig. This is consistent with CTLAo4 having higher avidity 
for B7 (26). 
CTLA-4 is expressed much less abundantly than its homo- 
logue, CD28. Expression was induced several hundred-fold 
upon activation. This finding is consistent with earlier studies 
(20, 23) which demonstrated an increase in CTLA-4  tran- 
script levels upon T  cell activation.  Even at  a maximum, 
CTLA-4 was expressed at only ~,1/30-50 the levels of CD28, 
as estimated in measurements of total (intracellular plus cell 
surface) CTLA-4 (Fig. 3), and cell surface CTLA-4 (Fig. 5). 
The difference  in expression  between CD28 and CTLA-4 sup- 
ports the earlier conclusion (14) that CD28 is the primary 
counter receptor for B7 on PHA-activated  T  cell blasts. 
Taken together, these results indicate that CTLA-4 is an 
activation-regulated counter receptor of high avidity and low 
abundance. CD28, on the other hand, is expressed on both 
resting and activated cells, and has lower avidity for B7, but 
higher abundance. The overall degree of interaction between 
B7 costimnlatory molecules on APC, and CD28 and CTLA-4 
on activated T cells would be determined  by the relative levels 
of the two T cell molecules. It is intriguing that the differ- 
ence in expression levels between CD28 and CTLA-4 on ac- 
tivated cells (30-50-fold) is similar in magnitude to the differ- 
ence in avidities of their respective Ig fusion proteins for B7 
(~20-fold; reference 26). This suggests that the difference 
in  avidities for  B7  between these  molecules  is  delicately 
balanced on activated T cells by differences in their levels of 
expression. 
Combinations of mAbs to CD28 and CTLA-4 coopera- 
tively inhibit adhesion of activated T cells to B7. Blocking 
CTLA-4 interactions with B7 therefore increased the ability 
of anti-CD28 mAbs to block CD28 interactions  with B7. 
This suggests that CD28 and CTLA-4 cooperatively regu- 
late adhesion to B7. Anti-CTLA-4 mAbs alone were poor 
inhibitors  of T  cell adhesion or proliferation  in MLC even 
though these mAbs blocked binding of CTLA4Ig to B7. Anti- 
CTLA-4 mAbs were also relatively inefficient at promoting 
T cell activation when coimmobilized with anti-TCR mAb. 
CTLA-4 interactions with B7 therefore are neither necessary 
nor sufficient for T cell adhesion or activation by B7. Con- 
versely, CD28 mAbs are good inhibitors  of adhesion and 
proliferation in MLC (39), and are potent costimulators  of 
T cell proliferation (6). This suggests that CD28-B7 inter- 
actions are essential for T  cell activation by APC. 
Our data suggest that one function of CTLA-4 on acti- 
vated T cells may therefore be to promote effective interac- 
tions between CD28 and B7. Low abundance, high avidity 
CTLA-4  molecules appear to facilitate interactions  and/or 
signals between higher abundance, lower avidity CD28 mol- 
ecules and the B7 counter receptor. One model to explain 
these data would be in which CTLA-4 and CD28 exist on 
the T cell surface in microdomains, as has been demonstrated 
for other adhesion molecules (41). The inclusion of CTLA-4 
in such microdomains might increase the probability of in- 
teraction between CD28 and B7 on the APC. Alternatively, 
B7 might exist in microdomains,  as has been suggested by 
immunofluorescence  studies  of certain  APC (Symington, 
F., W. Bradyl and P. S. Linsley, unpublished  observations). 
CTLA-4 might then bind to such a microdomain and thereby 
increase the probability  that it would interact with CD28 
on the T cell surface. A more complete understanding of the 
molecular mechanisms by which CTLA-4 facilitates T cell 
activation by CD28 will require careful investigation of the 
topography of CD28 and CTLA-4 on T cells, and of B7 on 
APC. 
Anti-CTLA-4 mAbs were less effective costimulators  of 
T cell proliferation than anti-CD28 mAb 9.3. We have also 
been unable to trigger intraceUular calcium mobilization or 
increases in IL-2 mKNA with anti-CTLA-4 mAbs under con- 
ditions that lead to clear signals with the anti-CD28  mAb 
9.3 (Greene, J., N. K. Demle, and P. S. Linsley, unpublished 
observations). This may result in part from the lower expres- 
sion of CTLA-4, but it may also indicate that signals trans- 
mitted by these two receptors are qualitatively different. The 
cytoplasmic domains of CD28 and CTLA-4 show somewhat 
limited sequence identity (26-29% for murine and human 
molecules; 23), possibly suggesting different interactions with 
signal-transducing molecules. It may also be significant that 
the cytoplasmic domains of murine and human CTLA-4 are 
identical (22, 23), whereas those from murine and human 
CD28 are only ~77% identical (40). This may reflect evolu- 
tionary pressure to conserve an essential signal-transducing 
function for CTLA-4. The anti-CTLA-4 mAbs we have de- 
scribed will facilitate future investigations on signal(s) trans- 
duced by this molecule. 
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